创新中药复方临床试验设计关键要素的思考与实践——基于1.1类中药复方制剂的启示

Reflections on key elements of clinical trial design for innovative Chinese medicine compound formulations：Insights from practice with category 1.1 Chinese compound preparations

关键词:  创新中药  临床试验  关键要素

Key words:  innovative Chinese medicine  clinical trial  key elements

摘要:

文章围绕1.1类创新复方中药临床试验设计难点，基于安神滴丸、安体威颗粒、青术颗粒、芪参益气滴丸等案例，系统梳理“理论-人群-疗程-指标-剂量”5个关键要素：1）以“辨证论治”精准锁定目标证候人群，实现“方-证-人”对应；2）依据基线疾病程度分层，引入安慰剂导入期/洗脱期，降低安慰剂效应、洗脱干扰；3）急性病抓住24~72 h“黄金窗口”，慢性病按“分期论治”设合适的疗程；4）构建“病-证-症”多维指标体系，以患者报告结局（PRO）、中医证候积分与硬终点互补，凸显中药整体调节优势；5）充分开展Ⅱ期剂量探索，揭示复方中药制剂非线性现象，并以“君臣佐使”“三因制宜”传统经验锚定起效剂量。文章提出突破化学药思维，用“协同攻坚”打破疗效天花板、“价值延伸”填补治疗空间，为创新复方中药提供可复制、可推广的临床试验设计范式。

Abstract:

Focusing on the design challenges of phase Ⅰ-Ⅲ trials for innovative 1.1-class Chinese-compound medicines，this article uses Anshen Dripping Pills，Antiwei Granules，Qingzhu Granules and Qishen Yiqi Dripping Pills as case studies to systematize five pivotal elements：“theory，population，treatment duration，end-points and dosage”，1）syndrome-based differentiation is employed to pinpoint the target population and achieve a precise“formula-syndrome-patient”match；2）stratification by baseline disease severity and the introduction of a placebo run-in/wash-out phase mitigate placebo effects and residual-drug interference；3）acute conditions are evaluated within the 24 h to 72 h“golden window”，whereas chronic diseases adopt a staged-treatment strategy with optimal durations； 4）a multi-dimensional“disease-syndrome-symptom”endpoint system that combines patient-reported outcomes，traditional Chinese medicine syndrome scores and hard clinical outcomes highlights the holistic benefits of herbal therapy；5）comprehensive phase Ⅱ dose-finding reveals non-linear dose-response relationships，while classical principles such as“sovereign-minister-assistant-courier” and“three-factor tailoring”anchor the minimal effective dose. The paper advocates moving beyond a chemical-drug mindset： “synergistic assault”to break through efficacy ceilings and“value extension”to fill unmet therapeutic gaps，offering a replicable and scalable clinical-trial paradigm for innovative Chinese-compound medicines.